Instructions for use Ulcavis
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION
INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINE Ulcavis® Ulcavis®
Registration number:
Trade name: Ulcavis®
International nonproprietary or generic name: bismuth tripotassium dicitrate
Dosage form: film-coated tablets
Composition per 1 tablet: Active ingredient: Tripotassium bismuth dicitrate 303.03 mg (equivalent to bismuth oxide 120.00 mg) Excipients: Corn starch, povidone K-30, potassium polykrilin, macrogol-6000, magnesium stearate Film coating: Opadry II transparent *, titanium dioxide (E171) *Opadray II transparent: polyvinyl alcohol, macrogol-4000, talc
Description Round, slightly biconvex, film-coated tablets of white or almost white color, odorless or with a faint odor of ammonia, with a bevel.
On the fracture there is a rough white mass.
Pharmacotherapeutic group: antiseptic intestinal and astringent ATC code: A02BX05
Pharmacological properties Pharmacodynamics Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces pepsin activity. Pharmacokinetics Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. It is excreted primarily through the intestines. A small amount of bismuth entering the blood plasma is excreted from the body by the kidneys.
Indications for use
- Peptic ulcer of the stomach and duodenum in the acute phase, including those associated with Helicobacter pylori.
- Chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori.
- Irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea.
- Functional dyspepsia not associated with organic diseases of the gastrointestinal tract.
Contraindications Severe renal failure (creatinine clearance less than 30 ml/min), pregnancy, breastfeeding, individual intolerance to the drug, children under 4 years of age.
Use during pregnancy and breastfeeding The use of Ulcavis® during pregnancy and breastfeeding is contraindicated.
Method of administration and dosage: For adults and children over 12 years of age, Ulcavis® is prescribed 1 tablet 4 times a day 30 minutes before meals and at night, or 2 tablets 2 times a day 30 minutes before meals. For children from 8 to 12 years old, Ulcavis® is prescribed 1 tablet 2 times a day 30 minutes before meals. Children from 4 to 8 years old are prescribed at a dose of 8 mg/kg/day; depending on the child’s body weight, 1-2 tablets per day are prescribed (respectively, in 1-2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). The tablets are taken 30 minutes before meals with a small amount of water. The duration of treatment is 4-8 weeks. You should not use medications containing bismuth for the next 8 weeks. To eradicate Helicobacter pylori, it is advisable to use the drug Ulcavis® in combination with other antibacterial agents that have anti-Helicobacter pylori activity (as recommended by a doctor).
Side effects From the digestive system: nausea, vomiting, more frequent bowel movements, constipation may occur. These phenomena are not dangerous to health and are temporary. Allergic reactions: skin rash, itching. With long-term use in high doses, the development of encephalopathy associated with the accumulation of bismuth in the central nervous system is possible.
Overdose When using the drug in doses tens of times higher than recommended, or with prolonged use of excessive doses of the drug, bismuth poisoning may develop. Symptoms: dyspepsia, skin rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums. An overdose of Ulcavis ® caused by long-term use of doses exceeding the recommended ones can lead to impaired renal function. These symptoms are completely reversible when the drug Ulcavis ® . Treatment: if signs of poisoning appear, it is necessary to rinse the stomach, take activated charcoal and saline laxatives. Further treatment should be symptomatic. In case of impaired renal function, which is accompanied by a high concentration of bismuth in the blood plasma, chelating agents (penicillamine, sodium dimercaptopropanesulfonate) can be prescribed. In case of severe renal dysfunction, hemodialysis is indicated.
Interaction with other drugs For half an hour before and after taking Ulcavis ® , it is not recommended to take other drugs orally, as well as take food and liquids, in particular antacids, milk, fruits and fruit juices. This is due to the fact that when taken orally simultaneously, they can affect the effectiveness of the drug Ulcavis ® . The simultaneous use of Ulcavis ® with tetracycline reduces the absorption of the latter.
Special instructions Ulcavis ® should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with Ulcavis ®, other medications containing bismuth should not be used. At the end of a course of treatment with Ulcavis ® in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 mcg/l, and intoxication is observed only when the concentration in the blood plasma is above 100 mcg/l. When using the drug Ulcavis ® , stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.
Effect on the ability to drive vehicles and machinery data on the effect of the drug Ulcavis ® on the ability to drive vehicles and machinery.
Release form: Film-coated tablets, 120 mg. 10 or 14 or 15 tablets in a blister made of combined material OPA/Al/PVC and aluminum foil. 2, 4, 8 and 16 blisters (blister of 14 tablets) or 3, 4, 6, 10 and 24 blisters (blister of 10 tablets), or 2, 4, 8 and 16 blisters (blister of 15 tablets) together with instructions for use are placed in a cardboard box.
Storage conditions At a temperature not exceeding 25 ºС, in the original packaging. Keep out of the reach of children.
Shelf life: 3 years. Do not use the drug after the expiration date.
Conditions of release Dispensed without a prescription.
Name and address of the holder (owner) of the registration certificate JSC "KRKA, d.d., Novo mesto", Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer (All stages of production) JSC "KRKA, d.d., Novo mesto", Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Name and address of the organization receiving consumer complaints LLC KRKA-RUS, 125212, Moscow, Golovinskoe highway, building 5, building 1 Tel., fax
Ulcavis tablets p/o 120 mg No. 14x8
Name
Ulcavis table cover. captivity vol. 120 mg per bl. in pack No. 14x8
Description
Round, slightly biconvex, film-coated tablets of white or almost white color, with a bevel. Fracture appearance: rough white mass with a white or almost white shell.
Main active ingredient
bismuth tripotassium dicitrate
Release form
pills
Dosage
For adults and children over 12 years of age, Ulcavis® is prescribed 1 tablet 4 times a day 30 minutes before meals and at night, or 2 tablets 2 times a day 30 minutes before meals. For children from 6 to 12 years old, Ulcavis® is prescribed at a dose of 8 mg/kg/day
special instructions
Ulcavis® should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with Ulcavis®, other medications containing bismuth should not be used. At the end of a course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 mcg/l, and intoxication is observed only when the concentration in the blood plasma is above 100 mcg/l. When using the drug Ulcavis®, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.
pharmachologic effect
antiulcer, anti-Helicobacter, gastroprotective.
Pharmacodynamics
Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of PGE, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces pepsin activity.
Pharmacokinetics
Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. It is excreted primarily through the intestines with feces. A small amount of bismuth entering the blood plasma is excreted from the body by the kidneys.
Indications for use
- peptic ulcer of the stomach and duodenum in the acute phase, incl. associated with Helicobacter pylori;
- chronic gastritis and gastroduodenitis in the acute phase, incl. associated with Helicobacter pylori;
- irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea;
- functional dyspepsia not associated with organic gastrointestinal diseases.
Directions for use and doses
Inside, 30 minutes before meals, with a small amount of water. For adults and children over 12 years of age, Ulcavis® is prescribed 1 tablet. 4 times a day 30 minutes before meals and at night or 2 tablets. 2 times a day. For children from 8 to 12 years old, Ulcavis® is prescribed 1 tablet. 2 times a day; from 4 to 8 years are prescribed at a dose of 8 mg/kg/day, depending on the child’s body weight, 1–2 tablets/day (respectively, in 1–2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). Duration of treatment is 4–8 weeks. Over the next 8 weeks, you should not use medications containing bismuth. To eradicate Helicobacter pylori, it is advisable to use the drug Ulcavis® in combination with other antibacterial agents that have anti-Helicobacter pylori activity (as recommended by a doctor).
Use during pregnancy and lactation
The use of Ulcavis® during pregnancy and breastfeeding is contraindicated.
Precautionary measures
Ulcavis® should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with Ulcavis®, other medications containing bismuth should not be used. At the end of a course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 mcg/l, and intoxication is observed only when the concentration in the blood plasma is above 100 mcg/l.
Interaction with other drugs
For half an hour before and after taking Ulcavis®, it is not recommended to take other drugs internally, as well as take food and liquids, in particular antacids, milk, fruits and fruit juices. This is due to the fact that when taken orally simultaneously, they can affect the effectiveness of the drug Ulcavis®. The simultaneous use of Ulcavis® with tetracycline reduces the absorption of the latter.
Contraindications
- individual intolerance to the drug;
- severe renal failure (creatinine Cl less than 30 ml/min);
- pregnancy;
- breastfeeding period;
- children under 4 years of age.
Compound
1 tab. bismuth tripotassium dicitrate 303.03 mg, which corresponds to the content of bismuth oxide 120 mg Excipients: corn starch - 72.17 mg, povidone K30 - 18 mg, potassium polykrilin - 23.8 mg, macrogol 6000 - 6 mg, magnesium stearate - 2 mg. Film shell composition: opadry II transparent - 8.5 mg (polyvinyl alcohol - 4.505 mg, macrogol 4000 - 2.295 mg, talc - 1.7 mg), titanium dioxide (E171) - 1.5 mg. 10 pieces. - blisters (3) - cardboard packs. 10 pieces. - blisters (4) - cardboard packs. 10 pieces. - blisters (6) - cardboard packs. 10 pieces. - blisters (10) - cardboard packs. 10 pieces. - blisters (24) - cardboard packs. 14 pcs. - blisters (2) - cardboard packs. 14 pcs. - blisters (4) - cardboard packs. 14 pcs. - blisters (8) - cardboard packs. 14 pcs. - blisters (16) - cardboard packs. 15 pcs. - blisters (2) - cardboard packs. 15 pcs. - blisters (4) - cardboard packs. 15 pcs. - blisters (8) - cardboard packs. 15 pcs. - blisters (16) - cardboard packs.
Overdose
Symptoms: dyspepsia, skin rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums. An overdose of Ulcavis®, caused by long-term use of doses exceeding the recommended ones, can lead to impaired renal function. These symptoms are completely reversible when Ulcavis® is discontinued. Treatment: gastric lavage, administration of activated charcoal and saline laxatives. Further treatment should be symptomatic. In case of impaired renal function, which is accompanied by a high concentration of bismuth in the blood plasma, chelating agents (penicillamine, sodium dimercaptopropanesulfonate) can be prescribed. In case of severe renal dysfunction, hemodialysis is indicated.
Side effect
From the digestive system: nausea, vomiting, more frequent bowel movements, and constipation may occur. These phenomena are not dangerous to health and are temporary. Allergic reactions: skin rash, itching. With long-term use in high doses, the development of encephalopathy associated with the accumulation of bismuth in the central nervous system is possible.
Storage conditions
At a temperature not exceeding 25 °C, in original packaging
